echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Roche Pharmaceuticals To Assist Digestive Oncology Drug Innovation For China Recruitment Partners Will Provide Funding, Drug and Research and Development Support

    Roche Pharmaceuticals To Assist Digestive Oncology Drug Innovation For China Recruitment Partners Will Provide Funding, Drug and Research and Development Support

    • Last Update: 2020-07-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Today,Roche PharmaceuticalsChina announced that, in order to meet the unfinished needs of China's vast number of patients with digestive tract tumors, and promote innovation in digestive tract oncology drugs, Roche will officially launch a special program for China's "DigestionTumorJoint Immune Treatment Cooperation Program" (the "Cooperative Special Program"), which will support Innovative Chinese enterprises in the development of new treatments forof gastrointestinaltumors, and provide funding, free drug research and other supportthe incidence of digestive tract tumors in China accounted for about 40% of the total incidence of tumors, significantly higher than the world average, many digestive tracttumorin China accounted for more than 50% of the total number of cases in the world, such asliver cancer, esophageal cancer, stomach cancer and so onIn addition, China's annual deaths due to gastrointestinal tumors accounted for 50% of the annual death son oftumor, most of the digestive tracttumorpatients's overall five-year survival rate is less than 20%, such as China's stomach cancer 5-year survival rate of 20%, liver cancer 5-year survival rate of 12.5%, esophageal cancer 5-year survival rate of 15%, and pancreatic cancer 5-year survival rate of only 7.2% "Roche has been investing in the field of digestive tract tumors and has been actively bringing a variety of innovative drugs to the digestive tract tumor to China In the face of the unfinished demands of the vast number of Chinese patients with digestive tumors, we look forward to supporting China to achieve more, faster and better breakthroughs in the field of digestive tumor treatment through this cooperation program Peter Ahnesorg, head of cancer at Roche Pharmaceuticals Global Digestive , said the Roche Digestive Tract Tumor Immunotherapy Joint Treatment Joint Treatment Joint Treatment Program will be open to all Chinese innovative pharmaceutical companies within 5 years, specific support methods include, but not limited to, the provision of Roche tumor immune products to Chinese pharmaceutical companies, such as the ®
    (Atilizhumono) and the target drug Amvitin ®
    (Bevalzumab) research drugs, through the domestic innovative pharmaceutical companies in the research of the drug research, the discovery of innovative of cancer The program will also provide research and development funding on the basis of mutual agreement, and roche pharmaceuticals will also provide scientific and research support to innovative pharmaceutical companies in China in the course of the partnership to help them optimize their strategies and accelerate the research and development process "With China's inclusion of biomedicine as a strategic industry and strong support for pharmaceutical innovation by the Chinese government, China is becoming a hotbed of global pharmaceutical innovation, with a global contribution of 7.8% to the number of new drugs developed in China," said Zhou Hong, president of Roche Pharmaceuticals China, a Roche Pharmaceuticals has long been rooted in China and actively explores cooperation with all parties, and the launch of this special program will also open the door to extensive cooperation between Roche and Chinese research institutions and local innovative enterprises "
    " Roche Digestive Tract Tumor Immune Joint Treatment Cooperation Program" partner: open application for all Chinese innovative pharmaceutical enterprises
    scope of cooperation/requirements: 1 Innovative molecules, innovative targets or innovative technologies
    2 The mechanism of action clear
    3 property rights / patent clear 4 Drug Joint scientific basis reasonable 5 Products have not yet been listed
    cooperation methods: 1 China's innovative pharmaceutical enterprises to provide the necessary pre-work data
    2 Roche Pharmaceutical signed a cooperation agreement after the evaluation of feasibility 3 Research and development by the applicant responsible for implementation, may also be negotiated by the two sides to take the best way to develop contact information: china.collaboration@roche.com
    about Roche's in the field
    of
    oncology in the digestive tract, as a leader in personalized medicine, Roche has been investing in the field of digestive tract oncology for a long time to develop innovative drugs, and has been actively bringing innovative drugs into China At present, Roche for stomach cancer, colorectal cancer of the Shiloda ®
    (Capetabin), Anvitin ®
    (Bevalzumab), Heseltine ®
    (qutozhu monotagatisisisisis) and other drugs have benefited tens of thousands of Chinese digestive tract tumor patients, tumor immune products Tai Sanqi ®
    (Atiliju monotagine) joint Anvi
    ®
    (Bebezhu monostatre) treatment in China is also expected to be approved for the treatment of advanced liver cancer In addition, Roche has conducted large-scale and innovative drug research and development in the field of digestive tumor such as colorectal cancer, esophageal cancer and bile duct cancer about Tesanchi
    ®
    atirezumab is a monoclonal antibody designed to bind directly to PD-L1 ligand proteins expressed on tumor cells and tumor -immersive immune cells, blocking its interaction with PD-1 and B7.1 receptors By blocking the PD-L1 pathway, the Tesanchi ®
    can effectively activate T cells As an innovative cancer immunotherapy, The tasty ®
    is expected to serve as a base drug for combination therapy, in combination with other immunotherapy, targeted drugs and various chemotherapy drugs for the treatment of a wide range of cancers at present, the ®
    of Tai Sanchi has been approved in the United States, the European Union and other countries in the world as a single-drug therapy or joint targeted therapy and/or chemotherapy for the treatment of non-small cell lung cancer and small cell lung cancer, specific types of metastatic urinary tract skin cancer and PD-L1 high expression of metastatic triple-negative breast cancer and other types of cancer On February 13, 2020, Tai Sanchi ®
    combined chemotherapy for first-line treatment of a wide range of small cell lung cancer was approved in China On February 28, China's State Drug Administration officially awarded The ®
    of Tai Sanchi joint avetin ®
    priority review for first-line treatment of advanced non-removable hepatocellular carcinoma ®
    on anavetine
    ®
    , a prescription drug that infusions through an vein, is a biological antibody that binds specifically to VEGF proteins, and VEGF plays an important role in angiogenesis and vascular maintenance throughout the life cycle of tumor , a process known as angiogenesis Anvitin ®
    interfere with the blood supply to tumors by binding directly to veGF proteins to prevent interactions with receptors on vascular cells The blood supply to tumor is considered to be key to the ability of tumor to grow and diffuse (metastasis) in the body has a solid scientific basis for the ®
    of the ta-san chi ®
    united anavetin ®
    tavet ®
    united Anvitin Together, they have the potential to improve the body's autoimmune system against a variety of tumors Anvirtin's anti-angiogenesis can further strengthen the immunotherapy of tumors in TaiSanchi, reduce VEFG-related immunosuppression, and improve the antigen response
    of T cells to tumors research on Roche's cancer immunotherapy
    For more than 50 years, Roche has been developing innovative drugs that redefine the treatment of cancer Today, we invest more than ever in developing innovative treatments to help activate patients
    autoimmune systems to fight cancer. roches is accelerating and expanding the clinical benefits of applying Tesanchi ®
    to a wider range of cancer patients by designing a framework for the cancer's immune cycle and conducting pioneering research in the field of tumor immunoassay Our cancer immunotherapy research uses a comprehensive approach to achieve the goal of rebuilding immunity against tumor to improve patient prognosis about the Roche Group Roche is a global leader in pharmaceutical and diagnostic , and is committed to improving human life by advancing science Combining the unique advantages of the pharmaceutical and diagnostic businesses makes Roche a leader in individualized medicine, providing the most targeted treatment options for every patient through personalized care Roche is the world's largest biotech company and has a leading differentiated drug in the areas of oncology , immune, infectious diseases, ophthalmology and central nervous system diseases Roche is a global leader in the field of in vitro diagnostic and tissue-based cancer diagnostic , and is a pioneer in diabetes management Since its founding in 1896, Roche has been continuously exploring better disease prevention, diagnostic and treatment options to continue to contribute to society At the same time, the company works closely with relevant stakeholders to improve patient access to innovative drugs In the WHO's essential medicines catalog, there are more than 30 medicines developed by Roche, including life-saving antibiotics
    , antimalarials and anti-
    tumor
    Furthermore, Roche has been one of the most sustainable companies in the Dow Jones Sustainability Index (DJSI) pharmaceutical industry for 11 consecutive years Headquartered in Basel, Switzerland, Roche has operations in more than 100 countries and will employ more than 98,000 people worldwide in 2019 In 2019, Roche invested 11.7 billion Swiss francs in research and development, with total sales of CHF 61.5 billion Genentech is a wholly owned subsidiary of Roche, which is also a controlling subsidiary of Chugai, Japan's Sinopharmaceutical Corporation For more information, please visit about Roche China's Roche's ties to China date back to the 1920s and 1930s, when roche began selling its drugs in Shanghai In 1994, Shanghai Roche Pharmaceutical Co., Ltd was officially established in Zhangjiang, Shanghai, becoming the first multinational company to enter Zhangjiang Hi-Tech Park In 2004, Roche Research and Development (China) Co., Ltd was established as the first multinational pharmaceutical company to set up a wholly-owned research and development center in Shanghai, and in 2007, Roche's Global Drug Development Shanghai Center was established to promote and accelerate the clinical development and registration of Roche's innovative drugs in China In 2009, the center joined Roche's Global Drug Development Center and became one of its five drug development centers worldwide in large multinational pharmaceutical companies, Roche has taken the lead in building a complete pharmaceutical value industry chain, including research, development, production, marketing and other links, to provide Chinese patients with anti-
    tumor , anti-infection and anti-viral, transplantation, rheumatism immunity and other key therapeutic areas of breakthrough drugs Currently, Roche has 22 products in China, covering 8 therapeutic areas based in China for the benefit of China and the world: Roche continues to increase its investment in China, especially in research and development innovation In 2015, Roche invested 863 million yuan to build the new Roche Shanghai Innovation Center, which was officially completed in 2019 The new Innovation Center focuses on research and early development of innovative drugs in the fields of immunity, inflammation and anti-infective diseases In the future, it will effectively promote Roche's collaboration with local research institutions and continue to develop innovative drugs for patients in China and around the world In addition, the Innovation Center is equipped with world-class research facilities to attract the influx of top innovative pharmaceutical talent at home and abroad With a commitment to "first patient needs", Shanghai is Roche's third-largest global strategic center after San Francisco and Basel with the deepening of reform and opening-up, the Chinese government has launched a series of new measures to the of health care reform, especially in speeding up the registration and approval process for new drugs and updating the national health insurance catalogue Currently, Roche has seven targeted drugs - Herceptin
    ®
    , Anvitin ®
    , Troquet
    ®
    , Zobovo ®
    , Ansa ®
    , ®
    , Merro ®
    and a biologic - which are listed in the National Health Insurance ®
    for the benefit of Chinese patients This not only greatly reduces the financial burden of cancer patients, but also promotes the standardization of the treatment of cancer in China Roche will actively work with governments, medical institutions and non-governmental organizations to explore innovative cooperation models that will benefit more Chinese patients through a series of influential and sustainable initiatives
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.